Oramed Pharmaceuticals Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated August 4, 2020, covers events occurring on August 3, 2020, regarding Oramed Pharmaceuticals Inc. (Nasdaq: ORMP). The filing details the outcomes of the Company's 2020 Annual Meeting of Stockholders and the subsequent filing of a Certificate of Amendment to its Certificate of Incorporation.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance actions and voting results.
Material Changes and Corporate Actions
- Stockholder Approvals: Stockholders approved the re-election of all seven director nominees, the Amended and Restated 2019 Stock Incentive Plan, and an amendment to the Certificate of Incorporation.
- Authorized Share Increase: The Company increased its authorized common stock from 30,000,000 shares to 60,000,000 shares. The Certificate of Amendment was filed and became effective on August 3, 2020.
- Compensation Advisory Vote: Stockholders approved the executive compensation advisory vote. Regarding the frequency of future votes, stockholders selected a two-year cycle (6,351,441 votes) over one-year or three-year options.
- Auditor Ratification: Kesselman & Kesselman (a member of PricewaterhouseCoopers International Limited) was ratified as the independent registered public accounting firm for the fiscal year ending August 31, 2020.
Voting Results Summary
| Proposal | For Votes | Against Votes | Abstain | Outcome |
|---|---|---|---|---|
| Re-election of Directors | Varied by nominee (approx. 7.2M each) | Varied by nominee (83k - 450k) | Varied by nominee | Approved |
| Amended 2019 Stock Incentive Plan | 6,726,213 | 862,685 | 175,097 | Approved |
| Amendment to Certificate of Incorporation | 13,692,827 | 1,477,875 | 480,134 | Approved |
| Executive Compensation (Say-on-Pay) | 7,275,546 | 299,671 | 188,778 | Approved |
| Frequency of Say-on-Pay Vote | 2 Years: 6,351,441 | 1 Year: 788,834 | 3 Years: 434,099 | 2-Year Cycle Selected |
| Ratification of Auditors | 15,215,757 | 162,310 | 272,769 | Approved |
Outlook, Risks, and Contingencies
The filing does not contain management commentary on business outlook, specific risks, or contingencies. The primary operational impact noted is the doubling of authorized shares, which provides the Company with greater flexibility for future equity issuances.
Key Facts for Investor Verification
- Verify the effective date of the Certificate of Amendment (August 3, 2020) to confirm the new authorized share count of 60,000,000.
- Review the Definitive Proxy Statement (Schedule 14A) filed on June 30, 2020, for detailed terms of the Amended and Restated 2019 Stock Incentive Plan.
- Note that the next advisory vote on executive compensation is scheduled for the 2022 Annual Meeting based on the two-year frequency selection.
- Confirm the appointment of Kesselman & Kesselman as the independent auditor for the fiscal year ending August 31, 2020.